This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Mekinist
  • /
  • Study of Selective BRAF Kinase Inhibitor Dabrafeni...
Clinical trial

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell

Read time: 3 mins
Last updated:1st Jun 2011
Identifier: NCT01336634
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest